AMENDMENTS

IN THE SPECIFICATION

The following paragraph replaces the 2nd full paragraph on page 2 of the Substitute Specification mailed on September 23, 2002:

The composition of the present disclosure comprises an active compound including ~~an active compound consisting of~~ alpha-hydroxypropionic acid, a pharmaceutical salt of alpha-hydroxypropionic acid, or a pharmaceutical catalyzer of alpha-hydroxypropionic acid, wherein the active compound may be~~or an acceptable pharmaceutical dilution thereof,~~ linked to an appropriate vehicle for application through the nasal cavities of a patient in need thereof. ~~The active compound utilized in the composition comes in an aqueous solution made of 15% water in 85% of acid.~~ The vehicle may be a serum or any other pharmaceutical capable of carrying the active compound through the nasal cavities. ~~The ideal composition of the vehicle is associated with is 70% of 1,2,3-propanotriol (glycerin) and 30% of 1,2-propanodiol (propilenoglycol).~~ A preferred vehicle comprises 1,2,3-propanotriol (glycerin), 1,2-propanodiol, and mixtures of at least one of the foregoing. ~~It has been detected that a~~Acceptable dilutions of the active compound in the vehicle are 0.2 ml to 104.0 ml of the active compound~~alpha-hydroxypropionic acid~~ for each 100 ml of the vehicle. Additionally, where the vehicle is 1,2-propanodiol, a particularly preferred dilution of the active compound in the vehicle is 0.2 ml to 10.0 ml of the active compound for each 10 ml of the vehicle.

The following paragraph replaces the 3rd full paragraph on page 2 of the Substitute Specification mailed on September 23, 2002:

The suggested dosage is in an amount that will result in desired effects obtained during the application of the composition. The composition may be taken by drops, spray, microfine powder, or as a pharmaceutical salt via the nasal airways~~, either in drops or in a spraying solution~~. As the application of the composition occurs at the nostrils, such a compound will work directly on the germs located in the nasal cavities and cheeks.

The following paragraph replaces the 4th full paragraph on page 2 of the Substitute Specification mailed on September 23, 2002:

The first application effect of the composition in the nasal cavities and cheekbones is dehydration of the germs that can be found there through its bactericide and bacteriostatic properties. After that, the hydrating and moistening effects of the composition cause the increase in the nasal mucosa elasticity and its clearance. The action motion of the alpha-hydroxypropionic acid keeps a more homogeneous cornea layer, decreasing the superficial cellular cohesion. The alpha-hydroxypropionic acid promotes a subtle exfoliation, leaving the nasal mucosa smoother and more homogeneous. Therefore, the composition may be used effectively as a nasal releaser. - no Sup. not defined